Catalyst Summit 2022 Canada’s conference on psychedelic medicine on May 20-22, 2022

Special Conference Discount for YOU

Have you heard of the Catalyst Summit 2022 happening on May 20-22. ATMA is proud to be a presenting sponsor of this event. As a thank you to our healthcare professionals for investing in yourselves and your clients to move this therapy forward, we are offering you a 30% discount off the regular price of the conference!

Get Discounted Tickets using the code CATALYST30

About Canada’s Premier Conference Dedicated to Psychedelic Medicine

The third annual Catalyst Summit is Canada’s premiere annual conference dedicated to psychedelic medicine and its growing role in medicine, society, and commerce. The conference is held at Queen’s University in Kingston, Ontario, and can also be attended virtually from anywhere. 

This year, there’s an impressive group of speakers and a schedule packed full of enlightening and informative topics all around psychedelics used in medicine. Take a look at some exciting things you can expect from this year’s event.

  • 50+ world leading experts are lined up to come and share insight into the latest research and science in psychedelics.
  • An overview of current and pending legislative and regulatory changes that are rapidly occurring within Canada and around the world. Plus hear from Health Canada during a panel discussion.
  • A range of perspectives on the therapeutic and medicinal uses and benefits of psychedelics with an emphasis on addressing mental and emotional health issues.
  • Exposure to some of Canada’s leading companies and organizations that are building the foundation for Canada’s psychedelic revolution in 2022 and beyond.
  • Historical context and background of different psychedelic compounds and elements, including Psilocybin, MDMA, Ketamine, LSD, Ayahuasca, 5Meo-DMT, Iboga, and others

Featured Event Speakers: VETS Founders Marcus and Amber

Speakers Marcus and Amber Capone, founder of VETS, will share their story about how they started an organization to help treat veterans with PTSD and traumatic brain injury through psychedelic therapy. VETS is an organization that provides resources, research, and advocacy for U.S. veterans seeking healing through psychedelic-assisted therapy alternatives in response to the growing veteran healthcare and suicide crises. Learn more about these speakers and their session on Saturday, May 21.

Learn More and Get Tickets

Attendees of the event will have access to keynote presentations, panel discussions, networking events, and more. If you are a healthcare professional in the field of psychedelic medicine or you want to learn more about it, this is the event you don’t want to miss. Get your tickets today!

More News and Media:

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

How To Change Your Mind

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public. At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Psilocybin-assisted Therapy: The Safe and Effective Alternative

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option

Magic Mushroom - ATMA

Magic Mushrooms (Psilocybin) and End-of-life

End-of-life distress has been an ongoing focus for psilocybin clinical trials, as psilocybin has the potential to offer relief for existential distress when other forms of treatment fail. Health Canada has granted access to psilocybin through the Section 56 Exemption program, which is a patient led application requesting access to psilocybin. These exemptions are reviewed

Is Training in Psychedelics Worth It?

Let’s start with a brief review of psychedelics, including what they are and how they differ from conventional Western medicine. There are many substances under the umbrella of psychedelics; the common ones are: Psilocybin (the active ingredient in magic mushrooms)  LSD (lysergic acid diethylamide) Ibogaine (the active ingredient in iboga) Mescaline (the active ingredient in

ATMA Submits Phase II Clinical Trial Application, Assessing Psilocybin Efficacy in Healthcare Professionals Suffering From COVID-19-Related Mental Wellness Challenges.

CALGARY, AB, May 10, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of its innovative psychedelic-assisted therapy solutions, announced the submission of its N-500 Phase II Psilocybin Clinical Trial to Health Canada today. This trial is aimed at studying the potential relief of COVID-19-associated mental health concerns in healthcare professionals, as well

Scroll to Top